Orthobiologics Patents: Leaders, Trends & White Space 2026
- 28.1% concentration at the top. The five leading assignees hold 1,333 of the 4,741 records in scope — a concentrated core sitting above a long tail of single- and few-filing entrants.
- Filing peaked in 2019 at 400 records. Volume has since eased, with 2021's 351 records falling to 190 by 2024 (-46%) — though 2025-2026 figures are still filling in under normal publication lag.
- A61K dominates at 79.6% of records. Medicinal-preparation claims touch four in five filings, while sterilising and disinfecting art (A61L) sits at just 2.6% — a visibly thinner branch.
Filing growth compares 2021 (351 records) with 2024 (190) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 4,741 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
Orthobiologics for soft tissue healing sits at the intersection of biologic preparation science and clinical protocol design: platelet-rich plasma, bone marrow aspirate and related biologic augmentation approaches, claimed alongside the preparation protocols, leukocyte-content controls, dosing regimens and regulatory or reimbursement pathways that determine whether a formulation is usable in practice. The dataset spans 2015 to the 2026 cut-off and captures 4,741 published records across this combined biologic-and-protocol claim space.
Because filing and publication are separated by roughly eighteen months, the most recent one to two years in any trend understate real activity. Reading the landscape by patent family rather than raw document count is the fairer approach here, since continuation practice and multi-jurisdiction filing can otherwise inflate a single underlying invention.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Trend and technology composition
The two views below — filings over time and technology classification — together show where claim density has built up and where it is still comparatively open.
A 2019 peak followed by a multi-year pullback
Filings rose from 205 records in 2017 to a peak of 400 in 2019, then eased; the 2021-to-2024 span shows 351 records falling to 190, a -46% change over three years. 2025 and 2026 figures will continue to fill in as publication catches up with filing, so treat the tail of the chart as provisional rather than a real slowdown.
A61K and A61P anchor the field; A61L is comparatively thin
Medicinal preparations (A61K) appear on 79.6% of the 4,741 records in scope, and therapeutic activity claims (A61P) on 49.2% — the two together frame most biologic-composition and indication claims. Peptide and protein chemistry (C07K, 34.1%) and microorganism/genetic-engineering art (C12N, 21.9%) form a substantial second tier. Sterilising and disinfecting art (A61L) covers only 2.6% of records, and heterocyclic-compound claims (C07D) sit at 5.8% — both comparatively under-built relative to the core preparation classes.
Shares are the percentage of the 4,741 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Orthobiologics for Soft Tissue Healing with Eureka
This page is one run against one query. Ask Eureka your own question about orthobiologics for soft tissue healing and every answer comes back with the patent numbers behind it.
Try EurekaMost-cited records and a recent representative filing
US20250243545A1 — In situ hybridization methods for use with frozen bone marrow aspirate
A method and apparatus for preparing a bone marrow aspirate (BMA) sample for detection of a targeted nucleic acid sequence including a first fixation step including contacting said BMA sample with a first fixation solution including formalin, and a second fixation step including contacting said BMA sample with a second fixation solution including methanol and acetic acid.Filed by Leica Biosystems Richmond, this record narrows in on sample-preparation chemistry for frozen bone marrow aspirate rather than the biologic formulation itself — a diagnostics-adjacent claim that sits close to, but distinct from, the therapeutic preparation art that dominates this landscape.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2016014565A2 | Treatment of cancer using humanized Anti-BCMA chimeric antigen receptor | 496 |
| 2 | US20160046724A1 | Treatment of cancer using humanized Anti-BCMA chimeric antigen receptor | 462 |
| 3 | WO2006138729A2 | Receptor antagonists for treatment of metastatic bone cancer | 322 |
| 4 | US20040126372A1 | Treatment of TNFalpha related disorders | 303 |
| 5 | US20040136991A1 | Treatment of anemia using TNFalpha inhibitors | 197 |
| 6 | WO2010080503A1 | Heterocyclic compounds and methods of use | 195 |
| 7 | US20080193466A1 | Treatment of Anemia Using TNFalpha Inhibitors | 166 |
| 8 | US20170174779A1 | Combination of Anti-PD-1 Antibodies and Anti-CD20/Anti-CD3 Antibodies to Treat Cancer | 145 |
| 9 | US20030219818A1 | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy | 140 |
| 10 | WO2017106656A1 | Antibody molecules to PD-1 and uses thereof | 131 |
Citation counts favour older filings simply by virtue of time in the corpus — they signal historical influence on the field, not which claims matter most today.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for filing strategy
Three figures shape how a new filer should read this field: how concentrated the top of the ranking is, where the technology classes cluster, and where the trend is heading once publication lag is accounted for.
The core is concentrated, the tail is long
The five leading assignees account for 1,333 of the 4,741 records in scope, and the top ten reach 42.6% (2,020 records). Beyond that the ranking thins quickly into single- and few-filing entrants, meaning most of the 100 ranked assignees hold only a handful of records each.
Volume has eased from its 2019 peak
Filings peaked at 400 records in 2019 and have declined since, with the complete 2021-2024 window showing a -46% change. Records from 2025 onward are still filling in under normal publication lag, so this should be read as a real pullback through 2024 rather than a continuing collapse.
Claims cluster around medicinal preparations
Medicinal-preparation claims (A61K) and therapeutic-activity claims (A61P, 49.2%) dominate the classification mix, while sterilising/disinfecting art (A61L, 2.6%) is comparatively sparse — a signal of where formulation-adjacent process claims remain open.
US and EPO lead, PCT close behind
The United States receives the most filings (1,040), followed by the EPO (630) and WIPO/PCT (591), with Australia, Israel and Canada forming a second tier. The spread across multiple receiving offices suggests filers are pursuing multi-jurisdiction protection rather than concentrating on a single market.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to orthobiologics for soft tissue healing, with the prior art for and against each one.
Who is filing, and where momentum sits now
The ranking is dominated by large biopharma and biotech names with therapeutic-antibody and cell-therapy portfolios that intersect this biologic-preparation claim space, sitting above a long tail of smaller and single-filing entrants.
A single leader well ahead of the field
The top-ranked assignee holds 324 records, well clear of the fifth-place holder at 164 and the tenth at 113 — a steep drop-off that marks a genuine leadership gap rather than a tight cluster at the top.
One dominant collaboration pair
Ten co-assignee pairs appear in the data, but one pair stands well apart with 273 shared records — far ahead of the next strongest pairs, which sit in the 50s. This points to a single deep, structured partnership rather than a broad web of alliances.
Momentum has cooled across the named leaders
Recent-year filing counts among the tracked leading assignees are low, with year-over-year changes ranging from flat to sharp declines. Given publication lag, this cooling should be read cautiously rather than as a definitive retreat from the space.
| Assignee | Recent year | YoY |
|---|---|---|
| Novartis AG | 1 | 0% |
| Regeneron Pharmaceuticals Inc | 1 | -92% |
| aTyr Pharma Inc | 0 | — |
| Iovance Biotherapeutics Inc | 0 | -100% |
| Pangu Biopharma Ltd | 0 | — |
| Portola Pharmaceuticals Inc | 0 | — |
| Celgene Corp | 0 | — |
| Kura Oncology Inc | 0 | — |
Where to take this analysis
The figures above frame the field; deciding where to file, partner or design around requires drilling into specific claims and assignee portfolios.
Map a freedom-to-operate position
Run the highest-cited records and the leading assignee's active family against a specific preparation protocol or dosing regimen to see what is actually blocked versus merely adjacent.
Explore in EurekaTrack the under-claimed branches
Sterilisation methods and reimbursement-pathway claims show comparatively thin classification density — worth monitoring for new entrants before the space fills in.
Set up a watch in EurekaWatch the co-filing pair
The strongest co-assignee relationship in this dataset spans 273 shared records — understanding its scope helps gauge how much of the leader's portfolio is jointly controlled.
Investigate in EurekaCommon questions on orthobiologics patenting
This dataset covers 4,741 published records filed between 2015 and the 2026 data cut-off, spanning platelet-rich plasma, bone marrow aspirate and related biologic augmentation approaches together with their preparation protocols, leukocyte-content controls and dosing regimens. The true current total is somewhat higher than shown, because publication typically lags filing by around eighteen months, so the most recent one to two years are still filling in. Treat 4,741 as the count of records published and indexed as of the cut-off, not a final tally for those most recent years.
The ranking covers 100 assignees, with the leader holding 324 records against 164 at fifth place and 113 at tenth — a clear gap between the top holder and the rest of the field. The top five combined account for 28.1% of all 4,741 records in scope, and the top ten reach 42.6%. Below that the ranking thins into a long tail of assignees with only a handful of filings each, which is typical of a field where large biopharma portfolios intersect with a broader base of smaller or single-invention filers.
Filings rose to a peak of 400 records in 2019 and have eased since; the clearest complete comparison is 2021's 351 records falling to 190 in 2024, a -46% change over that three-year span. Because publication lags filing by roughly eighteen months, 2025 and 2026 figures in the raw trend are understated and should not be read as evidence of a continuing decline. The honest read is a real pullback from the 2019 peak through 2024, with the more recent picture still incomplete.
Medicinal preparations (IPC class A61K) appear on 79.6% of the 4,741 records in scope, making it by far the most common classification, followed by therapeutic-activity claims (A61P) at 49.2% and peptide/protein chemistry (C07K) at 34.1%. Because a single record can carry several IPC classes, these shares add up to more than 100% — they describe overlapping claim coverage, not mutually exclusive categories. Sterilising and disinfecting art (A61L) is comparatively sparse at 2.6%, marking it as one of the thinner branches of the field.
The classification data points to sterilisation and disinfection methods (A61L, 2.6% of records) and heterocyclic adjunct compounds (C07D, 5.8%) as comparatively under-built relative to the dominant medicinal-preparation and therapeutic-activity classes. Process-level claims around leukocyte-content control, dosing-regimen standardisation, and regulatory or reimbursement pathways also appear less saturated than the core biologic-composition art. A new filer is better placed searching these narrower process and protocol angles than competing directly on broad biologic-preparation composition claims, where the leading assignees already hold dense portfolios.
Research Orthobiologics for Soft Tissue Healing in depth with Eureka
Go past this page: query the whole orthobiologics for soft tissue healing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.